Cargando…

Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial

PURPOSE: Compared to a healthy population, the gut microbiota in type 2 diabetes presents with several unfavourable features that may impair glucose regulation. The aim of this study was to evaluate the prebiotic effect of inulin-type fructans on the faecal microbiota and short-chain fatty acids (SC...

Descripción completa

Detalles Bibliográficos
Autores principales: Birkeland, Eline, Gharagozlian, Sedegheh, Birkeland, Kåre I., Valeur, Jørgen, Måge, Ingrid, Rud, Ida, Aas, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501097/
https://www.ncbi.nlm.nih.gov/pubmed/32440730
http://dx.doi.org/10.1007/s00394-020-02282-5
_version_ 1783583985102749696
author Birkeland, Eline
Gharagozlian, Sedegheh
Birkeland, Kåre I.
Valeur, Jørgen
Måge, Ingrid
Rud, Ida
Aas, Anne-Marie
author_facet Birkeland, Eline
Gharagozlian, Sedegheh
Birkeland, Kåre I.
Valeur, Jørgen
Måge, Ingrid
Rud, Ida
Aas, Anne-Marie
author_sort Birkeland, Eline
collection PubMed
description PURPOSE: Compared to a healthy population, the gut microbiota in type 2 diabetes presents with several unfavourable features that may impair glucose regulation. The aim of this study was to evaluate the prebiotic effect of inulin-type fructans on the faecal microbiota and short-chain fatty acids (SCFA) in patients with type 2 diabetes. METHODS: The study was a placebo controlled crossover study, where 25 patients (15 men) aged 41–71 years consumed 16 g of inulin-type fructans (a mixture of oligofructose and inulin) and 16-g placebo (maltodextrin) for 6 weeks in randomised order. A 4-week washout separated the 6 weeks treatments. The faecal microbiota was analysed by high-throughput 16S rRNA amplicon sequencing and SCFA in faeces were analysed using vacuum distillation followed by gas chromatography. RESULTS: Treatment with inulin-type fructans induced moderate changes in the faecal microbiota composition (1.5%, p = 0.045). A bifidogenic effect was most prominent, with highest positive effect on operational taxonomic units (OTUs) of Bifidobacterium adolescentis, followed by OTUs of Bacteroides. Significantly higher faecal concentrations of total SCFA, acetic acid and propionic acid were detected after prebiotic consumption compared to placebo. The prebiotic fibre had no effects on the concentration of butyric acid or on the overall microbial diversity. CONCLUSION: Six weeks supplementation with inulin-type fructans had a significant bifidogenic effect and induced increased concentrations of faecal SCFA, without changing faecal microbial diversity. Our findings suggest a moderate potential of inulin-type fructans to improve gut microbiota composition and to increase microbial fermentation in type 2 diabetes. TRIAL REGISTRATION: The trial is registered at clinicaltrials.gov (NCT02569684). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00394-020-02282-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7501097
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-75010972020-10-01 Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial Birkeland, Eline Gharagozlian, Sedegheh Birkeland, Kåre I. Valeur, Jørgen Måge, Ingrid Rud, Ida Aas, Anne-Marie Eur J Nutr Original Contribution PURPOSE: Compared to a healthy population, the gut microbiota in type 2 diabetes presents with several unfavourable features that may impair glucose regulation. The aim of this study was to evaluate the prebiotic effect of inulin-type fructans on the faecal microbiota and short-chain fatty acids (SCFA) in patients with type 2 diabetes. METHODS: The study was a placebo controlled crossover study, where 25 patients (15 men) aged 41–71 years consumed 16 g of inulin-type fructans (a mixture of oligofructose and inulin) and 16-g placebo (maltodextrin) for 6 weeks in randomised order. A 4-week washout separated the 6 weeks treatments. The faecal microbiota was analysed by high-throughput 16S rRNA amplicon sequencing and SCFA in faeces were analysed using vacuum distillation followed by gas chromatography. RESULTS: Treatment with inulin-type fructans induced moderate changes in the faecal microbiota composition (1.5%, p = 0.045). A bifidogenic effect was most prominent, with highest positive effect on operational taxonomic units (OTUs) of Bifidobacterium adolescentis, followed by OTUs of Bacteroides. Significantly higher faecal concentrations of total SCFA, acetic acid and propionic acid were detected after prebiotic consumption compared to placebo. The prebiotic fibre had no effects on the concentration of butyric acid or on the overall microbial diversity. CONCLUSION: Six weeks supplementation with inulin-type fructans had a significant bifidogenic effect and induced increased concentrations of faecal SCFA, without changing faecal microbial diversity. Our findings suggest a moderate potential of inulin-type fructans to improve gut microbiota composition and to increase microbial fermentation in type 2 diabetes. TRIAL REGISTRATION: The trial is registered at clinicaltrials.gov (NCT02569684). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00394-020-02282-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-05-21 2020 /pmc/articles/PMC7501097/ /pubmed/32440730 http://dx.doi.org/10.1007/s00394-020-02282-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Contribution
Birkeland, Eline
Gharagozlian, Sedegheh
Birkeland, Kåre I.
Valeur, Jørgen
Måge, Ingrid
Rud, Ida
Aas, Anne-Marie
Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
title Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
title_full Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
title_fullStr Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
title_full_unstemmed Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
title_short Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
title_sort prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial
topic Original Contribution
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501097/
https://www.ncbi.nlm.nih.gov/pubmed/32440730
http://dx.doi.org/10.1007/s00394-020-02282-5
work_keys_str_mv AT birkelandeline prebioticeffectofinulintypefructansonfaecalmicrobiotaandshortchainfattyacidsintype2diabetesarandomisedcontrolledtrial
AT gharagozliansedegheh prebioticeffectofinulintypefructansonfaecalmicrobiotaandshortchainfattyacidsintype2diabetesarandomisedcontrolledtrial
AT birkelandkarei prebioticeffectofinulintypefructansonfaecalmicrobiotaandshortchainfattyacidsintype2diabetesarandomisedcontrolledtrial
AT valeurjørgen prebioticeffectofinulintypefructansonfaecalmicrobiotaandshortchainfattyacidsintype2diabetesarandomisedcontrolledtrial
AT mageingrid prebioticeffectofinulintypefructansonfaecalmicrobiotaandshortchainfattyacidsintype2diabetesarandomisedcontrolledtrial
AT rudida prebioticeffectofinulintypefructansonfaecalmicrobiotaandshortchainfattyacidsintype2diabetesarandomisedcontrolledtrial
AT aasannemarie prebioticeffectofinulintypefructansonfaecalmicrobiotaandshortchainfattyacidsintype2diabetesarandomisedcontrolledtrial